Industries de la santé

Engineered bacteria can make the ultimate sacrifice

Imprimer PDF

Écrit par EMBO | 20 Novembre 2012

HEIDELBERG, 20 November 2012 – Scientists have engineered bacteria that are capable of sacrificing themselves for the good of the bacterial population. These altruistically inclined bacteria, which are described online in the journal Molecular Systems Biology, can be used to demonstrate the conditions where programmed cell death becomes a distinct advantage for the survival of the bacterial...

Lire la suite... Ajouter un commentaire

Chronic Disease Patients Treated Drip by Drip

Imprimer PDF

Écrit par GBI | 15 Novembre 2012

NEW YORK (GBI Research), 15 November 2012 - Intravenous (IV) drips are fast evolving, as patients take their treatment in to the home, states a new report by healthcare experts GBI Research.




The new report* states that diseases such as cancer, Acquired Immune Deficiency Syndrome (AIDS) and Gastrointestinal (GI) disorders are becoming more common, due in part to a globally ageing...

Lire la suite... Ajouter un commentaire

Biologics and Stem Cell Research Boost the Cell Culture Market

Imprimer PDF

Écrit par GBI | 13 Novembre 2012

NEW YORK (GBI Research), 13 November 2012

Cell culture is becoming the next big pharmaceutical trend, as laboratories rush to meet demand for stem cell and biologics, states a new report by healthcare experts GBI Research. The new report* looks at cell culture, which involves the isolation of animal or plant cells, for their growth in an artificial environment where conditions such as...

Lire la suite... Ajouter un commentaire

Développement d'un nouveau traitement de l'hypercholestérolémie familiale homozygote (HoFH)

Imprimer PDF

Écrit par Aegerion Pharmaceuticals Inc | 31 Octobre 2012

FDA Advisory Committee Recommends Approval of Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia HoFH



October 30 - Aegerion Pharmaceuticals, Inc., une récente start-up de biotech pharmaceutique, dédiée au développement d'un nouveau traitement de l'hypercholestérolémie familiale homozygote (HoFH), maladie  rare très invalidante et souvent mortelle, annonce que...

Lire la suite... Ajouter un commentaire

Esbriet (pirfénidone), premier médicament autorisé chez l’adulte dans le traitement de la fibrose pulmonaire idiopathique légère à modérée (CVF ≥ 50 % et DLCO ≥ 35 %)

Imprimer PDF

Écrit par InterMune | 26 Octobre 2012

Esbriet® (pirfénidone) indiqué chez l’adulte dans le traitement de la fibrose pulmonaire idiopathique légère à modérée (CVF ≥ 50 % et DLco ≥ 35 %).
- La fibrose pulmonaire idiopathique (FPI) est une maladie rare, mais dont le pronostic est aussi sombre que celui de nombreux cancers fréquents. La médiane de survie varie de 2 à 5 ans suivant le diagnostic. Près de 10 000...

Lire la suite... Commentaires (2)

Novozymes reports EBIT growth of 12%

Imprimer PDF

Écrit par Novozymes | 25 Octobre 2012

COPENHAGEN, DENMARK - October 25, 2012 - Novozymes, the world leader in bioinnovation and industrial enzymes, today reported sales growth of 6% in DKK for the first 9 months of 2012. EBIT grew by 12% compared with the first 9 months of 2011, increasing the EBIT margin to 24.6%. The expectations for full-year 2012 EBIT growth, EBIT margin and net profit growth are maintained, as is the...

Lire la suite... Ajouter un commentaire

Safe Orthopaedics introducing SteriSpine™ PS Pedicle System at North American Spine Society Meeting

Imprimer PDF

Écrit par Safe Orthopaedics | 24 Octobre 2012

DALLAS / Privately held Safe Orthopaedics aims to revolutionize the way orthopedic and spinal implant systems are delivered by introducing the SteriSpine™ PS Pedicle Screw system — the world’s first single-use, sterile and traceable system for fixation of the lumbar spine — at the North American Spine Society (NASS) Meeting in Dallas this October 24-27.

“The introduction of...

Lire la suite... Ajouter un commentaire

DIA China to Host Workshop on Statistical Methodologies in Clinical Trials

Imprimer PDF

Écrit par DIA | 23 Octobre 2012

BEIJING, CHINA—OCTOBER 23, 2012— DIA, the premier organization dedicated to knowledge exchange that fosters innovation to raise the level of health and well-being worldwide will host the 2012 Statistical Workshop, two days focusing on understanding the statistical thinking in clinical research for drug development and control overall false positive rate in clinical trials to ensure...

Lire la suite... Ajouter un commentaire

Analyst Insight: ECTRIMS 2012 Congress Highlights: Promising Data Offers Hope for Progressive MS

Imprimer PDF

Écrit par GlobalData | 22 Octobre 2012

LONDON, UK (GlobalData), 22 October 2012 - The 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) played host to promising data that aim to address one of the greatest unmet needs in Multiple Sclerosis (MS): the treatment for progressive forms of the disease. Although Primary-Progressive MS (PPMS) afflicts only 10%–15% of the MS...

Lire la suite... Ajouter un commentaire

Plus d'articles...

Information

Annuaires

Vitrines Sociétés

Voir toutes les vitrines